
浏览全部资源
扫码关注微信
1.河南中医药大学第一附属医院肝病(脾胃)诊疗中心,郑州;450006
2.河南中医药大学第一临床医学院,郑州 450046
3.河南省中医药科学院,郑州 450046
4.中西医防治重大疾病河南省协同创新中心,郑州 450046
5.豫药全产业链研发河南省协同创新中心,郑州 450046
博士研究生。研究方向:中医药防治消化疾病。 E-mail:g18206481922@163.com
教授,博士生导师,博士。研究方向:中医药防治肝胆病的临床与机制。E-mail:liumh015@163.com
收稿:2025-12-24,
修回:2026-03-06,
录用:2026-03-14,
纸质出版:2026-04-15
移动端阅览
管雅捷,张琪振,徐俊姣,等.化痰祛湿活血方抑制巨噬细胞焦亡改善代谢相关脂肪性肝炎的作用机制研究 [J].中国药房,2026,37(07):864-869.
GUAN Yajie,ZHANG Qizhen,XU Junjiao,et al.Study on the mechanism of Huatan qushi huoxue formula in improving metabolic dysfunction-associated steatohepatitis by inhibiting macrophage pyroptosis[J].ZHONGGUO YAOFANG,2026,37(07):864-869.
管雅捷,张琪振,徐俊姣,等.化痰祛湿活血方抑制巨噬细胞焦亡改善代谢相关脂肪性肝炎的作用机制研究 [J].中国药房,2026,37(07):864-869. DOI: 10.6039/j.issn.1001-0408.2026.07.07.
GUAN Yajie,ZHANG Qizhen,XU Junjiao,et al.Study on the mechanism of Huatan qushi huoxue formula in improving metabolic dysfunction-associated steatohepatitis by inhibiting macrophage pyroptosis[J].ZHONGGUO YAOFANG,2026,37(07):864-869. DOI: 10.6039/j.issn.1001-0408.2026.07.07.
目的
2
聚焦NOD样受体蛋白3/胱天蛋白酶1/消皮素D(NLRP3/Caspase-1/GSDMD)经典焦亡通路,探讨化痰祛湿活血方(HQHF)抑制巨噬细胞焦亡改善代谢相关脂肪性肝炎(MASH)的作用机制。
方法
2
将RAW264.7细胞分为Control组(10%空白血清)、Model组[10%空白血清+5 μg/mL脂多糖(LPS)]、HQHF-L组(2.5%含药血清+7.5%空白血清+5 μg/mL LPS)、HQHF-M组(5%含药血清+5%空白血清+5 μg/mL LPS)、HQHF-H组(10%含药血清+5 μg/mL LPS)。给药后常规培养24 h,收集细胞及细胞培养上清液。采用扫描电子显微镜和相差荧光显微镜观察细胞形态;采用免疫荧光法观察消皮素D-N端(GSDMD-N)蛋白的定位与表达;采用酶联免疫吸附测定法检测细胞培养上清液中白细胞介素1β(IL-1β)、IL-18含量;采用实时荧光定量聚合酶链式反应法和Western blot法检测细胞中NLRP3、Caspase-1、GSDMD的mRNA及其蛋白表达。
结果
2
与Control组比较,Model组细胞呈现典型焦亡形态,GSDMD-N蛋白在细胞膜聚集且荧光强度显著增强(
P
<0.05),细胞培养上清液中IL-1β、IL-18含量均显著升高(
P
<0.05),细胞中NLRP3、Caspase-1、GSDMD mRNA及其蛋白表达均显著上调(
P
<0.05)。与Model组比较,HQHF-L、HQHF-M、HQHF-H组细胞的焦亡形态改善,细胞中GSDMD-N蛋白的膜定位减少且荧光强度显著减弱(
P
<0.05),细胞培养上清液中IL-1β、IL-18含量均显著降低(
P
<0.05),细胞中NLRP3、Caspase-1、GSDMD mRNA及其蛋白表达均显著下调(
P
<0.05)。
结论
2
化痰祛湿活血方能抑制LPS诱导的巨噬细胞焦亡,其改善MASH的作用机制可能与抑制NLRP3/Caspase-1/GSDMD经典焦亡通路的激活相关。
OBJECTIVE
2
To focus on the classic NOD-like receptor protein 3 (NLRP3)/Caspase-1/gasdermin D (GSDMD) pyroptosis pathway and explore the mechanism by which Huatan qushi huoxue formula (HQHF) inhibits macrophage pyroptosis to ameliorate metabolic dysfunction-associated steatohepatitis (MASH).
METHODS
2
RAW264.7 cells were divided into 5 groups: Control group (10% blank serum), Model group [10% blank serum+5 μg/mL lipopolysaccharide (LPS)], HQHF-L group (2.5% drug-containing serum+7.5% blank serum+5 μg/mL LPS), HQHF-M group (5% drug-containing serum+5% blank serum+5 μg/mL LPS), and HQHF-H group (10% drug-containing serum+5 μg/mL LPS). After 24 h of routine culture post-administration, cells and supernatants were collected for assays. Cell morphology was observed via scanning electron microscopy and phase-contrast microscopy; localization and expression of gasdermin D-N (GSDMD-N) were observed by immunofluorescence. Interleukin-1β (IL-1β) and IL-18 contents in supernatants were detected by ELISA; mRNA and protein expressions of NLRP3, Caspase-1, and GSDMD were measured using real-time PCR and Western blot.
RESULTS
2
Compared with the Control group, the Model group showed typical pyroptotic morphology (cell membrane bulging and pore formation), increased aggregation and fluorescence intensity of GSDMD-N on the cell membrane (
P
<0.05), significantly increased the contents of IL-1β and IL-18 in cell supernatants (
P
<0.05), and significantly up-regulated mRNA and protein expressions of NLRP3, Caspase-1, and GSDMD in cells (
P
<0.05). Compared with the Model group, the HQHF-L, HQHF-M and HQHF-H groups showed improved pyroptotic morphology, reduced membrane localization and significantly weakened fluorescence intensity of GSDMD-N (
P
<0.05), significantly decreased the contents of IL-1β and IL-18 in cell supernatants (
P
<0.05), and significantly down-regulated mRNA and protein expressions of NLRP3, Caspase-1, and GSDMD in cells (
P
<0.05).
CONCLUSIONS
2
HQHF inhibits LPS-induced macrophage pyroptosis, and its mechanism of improving MASH may be associated with the suppression of the activation of the classical NLRP3/Caspase-1/GSDMD pyroptosis pathway.
COTTER T G , RINELLA M . Nonalcoholic fatty liver disease 2020:the state of the disease [J ] . Gastroenterology , 2020 , 158 ( 7 ): 1851 - 1864 .
BARREBY E , CHEN P , AOUADI M . Macrophage functional diversity in NAFLD-more than inflammation [J ] . Nat Rev Endocrinol , 2022 , 18 ( 8 ): 461 - 472 .
MRIDHA A R , WREE A , ROBERTSON A A B , et al . NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice [J ] . J Hepatol , 2017 , 66 ( 5 ): 1037 - 1046 .
LUO R X , HU Y D , WANG L , et al . Penthorum chinense Pursh extract ameliorates hepatic steatosis by suppressing pyroptosis via the NLRP3/Caspase-1/GSDMD pathway [J ] . Food Sci Nutr , 2024 , 12 ( 7 ): 5176 - 5187 .
GAUL S , LESZCZYNSKA A , ALEGRE F , et al . Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis [J ] . J Hepatol , 2021 , 74 ( 1 ): 156 - 167 .
ZHAO Q , DAI M Y , HUANG R Y , et al . Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice [J ] . Nat Commun , 2023 , 14 ( 1 ): 1829 .
DONG L , ZHANG H T , KANG Y Y , et al . NLRP3 and gut-liver axis:new possibility for the treatment of alcohol-associated liver disease [J ] . J Gastroenterol Hepatol , 2025 , 40 ( 5 ): 1070 - 1078 .
WANG F , RUAN D Y , XU R H . Challenges and oppor- tunities in oncology drug development and clinical research in China [J ] . Cell , 2024 , 187 ( 7 ): 1578 - 1583 .
刘鸣昊 , 刘素彤 , 尚东方 , 等 . 化痰祛湿活血方对脂多糖诱导的巨噬细胞焦亡形态的影响 [J ] . 临床肝胆病杂志 , 2022 , 38 ( 9 ): 2016 - 2019 .
马庆亮 , 张丽慧 , 刘鸣昊 , 等 . 化痰祛湿活血方含药血清对HepG 2.2.15细胞乙型肝炎病毒复制能力及脂肪代谢相关基因表达的影响 [J ] . 中医杂志 , 2021 , 62 ( 7 ): 622 - 627 .
ARGENZIANO M E , KIM M N , MONTORI M , et al . Epidemiology,pathophysiology and clinical aspects of hepatocellular carcinoma in MAFLD patients [J ] . Hepatol Int , 2024 , 18 ( Suppl.2 ): 922 - 940 .
NUSSE Y , KUBES P . Liver macrophages:development,dynamics,and functions [J ] . Cell Mol Immunol , 2025 , 22 ( 10 ): 1178 - 1189 .
FILIPOVIC B , MARJANOVIC-HALJILJI M , MIJAC D , et al . Molecular aspects of MAFLD-new insights on pathogenesis and treatment [J ] . Curr Issues Mol Biol , 2023 , 45 ( 11 ): 9132 - 9148 .
AL MAMUN A , AKTER A , HOSSAIN S , et al . Role of NLRP3 inflammasome in liver disease [J ] . J Dig Dis , 2020 , 21 ( 8 ): 430 - 436 .
姚树坤 , 刘婧 , 周天惠 . 代谢相关脂肪性肝病的发病机制与中医病机 [J ] . 临床肝胆病杂志 , 2024 , 40 ( 10 ): 1954 - 1958 .
FARRELL G C , VAN ROOYEN D , GAN L , et al . NASH is an inflammatory disorder:pathogenic,prognostic and therapeutic implications [J ] . Gut Liver , 2012 , 6 ( 2 ): 149 - 171 .
TILG H , MOSCHEN A R , RODEN M . NAFLD and diabetes mellitus [J ] . Nat Rev Gastroenterol Hepatol , 2017 , 14 ( 1 ): 32 - 42 .
LIU S T , ZHANG L H , XU J J , et al . Identification of ferroptosis-related genes in MAFLD/MASH and HQHF validation [J ] . Hepat Med , 2025 , 17 : 13 - 24 .
刘素彤 , 张丽慧 , 顾亚娇 , 等 . 化痰祛湿活血方对非酒精性脂肪性肝炎大鼠模型肝细胞线粒体超微结构的影响 [J ] . 临床肝胆病杂志 , 2022 , 38 ( 8 ): 1780 - 1783 .
管雅捷 , 张丽慧 , 刘素彤 , 等 . 基于网络药理学和动物实验探究化痰祛湿活血方治疗非酒精性脂肪性肝炎的作用机制 [J ] . 医学研究杂志 , 2025 , 54 ( 5 ): 52 - 59 .
0
浏览量
132
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621